High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.
1] Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Department of Oncological Sciences, H. Lee Moffitt Cancer Center/University of South Florida College of Medicine, Tampa, FL, USA.
T
T
Nishihori
Division of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Y
Y
Hassoun
Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
L
L
Zhang
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
K
K
Shain
1] Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Department of Oncological Sciences, H. Lee Moffitt Cancer Center/University of South Florida College of Medicine, Tampa, FL, USA.
M
M
Alsina
1] Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Department of Oncological Sciences, H. Lee Moffitt Cancer Center/University of South Florida College of Medicine, Tampa, FL, USA.
M A
MA
Kharfan-Dabaja
D001853:Bone Marrow / Q000473:pathology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000737:chemistry; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics*; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000235:genetics* / Q000628:therapy*; D009154:Mutation; D019653:Myeloablative Agonists / Q000008:administration & dosage; D010976:Platelet Count; D013920:Thrombocythemia, Essential / Q000150:complications / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome
D019653:Myeloablative Agonists; D016179:Granulocyte Colony-Stimulating Factor; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D008558:Melphalan; D006918:Hydroxyurea